Lightbridge Corporation — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; filed May 12, 2022. Lightbridge is developing metallic nuclear fuel and remains in the research and development stage, with no commercial revenue.
Financial results and position
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2.18 million | $2.15 million |
| Operating loss | $2.05 million | $2.05 million |
| Net loss | $2.05 million | $2.01 million |
| Net loss per common share | $0.20 | $0.33 |
| Operating cash used | $1.93 million | $6.30 million |
| Cash and cash equivalents, March 31 | $28.23 million | $15.24 million at March 31, 2021 |
| Total current liabilities | $0.45 million | $0.17 million at December 31, 2021 |
| Debt | None reported | No debt or lines of credit |
Cash increased $3.48 million from year-end 2021, primarily reflecting $5.41 million net proceeds from ATM share sales, partly offset by operating cash use. Working capital was approximately $28.3 million. No meaningful revenue-based margin is available because the company had no revenue.
Changes and notable items
- General and administrative expense rose about 6% to $1.91 million, while R&D expense declined about 25% to $0.26 million. Total operating expenses were broadly flat.
- Basic and diluted loss per share improved to $0.20 from $0.33, while net loss increased modestly. The prior-year common-shareholder loss included preferred-stock dividends and a deemed dividend; those items were absent in Q1 2022.
- The company sold approximately 820,641 shares through its ATM offering for $5.41 million net proceeds. Shares outstanding rose to 10,588,674 at quarter-end from 9,759,223 at year-end 2021.
- Q1 2022 stock-based compensation was approximately $0.26 million, versus $0.06 million a year earlier. DOE-supported contributed R&D services of approximately $0.12 million were recorded as other operating income with a corresponding R&D expense.
Outlook, risks and contingencies
- Management stated that available working capital exceeded anticipated expenditures through Q1 2023, but also concluded that substantial doubt exists about the company’s ability to continue as a going concern for the 12 months following the filing. It expects continued negative operating cash flow and ongoing losses.
- Management estimates operating cash outflows of about $1.0–$1.2 million monthly and total expenditures of approximately $12–$18 million over the next 12–15 months. Longer-term development may require about $10 million of outside R&D spending annually for 10–15 years. These are estimates, not assurances.
- Funding plans include ATM or other equity issuance, possible debt or convertible financing, strategic relationships, and government grants. Financing availability is uncertain; equity issuance could dilute shareholders. Delaying R&D could reduce cash use but extend the fuel-development timeline.
- The PNNL/DOE GAIN project to demonstrate the fuel-casting process was expected to finish by Q3 2022. The project value is approximately $0.7 million, with about three-quarters expected from DOE.
- Key risks include technical, regulatory, commercialization and funding uncertainty; reliance on national laboratories and strategic partners; competition; COVID-19-related delays; and protection of intellectual property. The filing highlights uncertainty about maintaining Russian and Eurasian patents amid sanctions and Russian legal changes.
- The company reported no legal proceedings believed likely to have a material adverse effect. It reported effective disclosure controls and no material first-quarter change in internal control over financial reporting.
Important facts for investors to verify
- Whether ATM capacity, public-float limitations, market conditions, and subsequent share issuance can support the company’s stated cash needs.
- Whether DOE grants, strategic partners, and national-laboratory agreements provide the funding and project progress assumed in management’s plans.
- Actual cash burn and R&D commitments as agreements are finalized, including whether management must reduce or defer development work.
- Progress and results of the PNNL casting project and the broader fuel-testing and commercialization timeline.
- Developments affecting patent maintenance and enforceability in Russia and Eurasia, as well as potential dilution from equity awards and future financing.